TL;DR CNBC

Ticker: ESALY

2024-09-08 08:00:01 Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment MIXED BIIB, 4523.T-JP, ESALY,	2024-04-24 10:26:32 Biogen tops profit estimates as cost cuts take hold, Alzheimer's drug Leqembi launch picks up POSITIVE ESALY, 4523.T-JP, BIIB,	2024-02-20 14:15:29 Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start MIXED BIIB, 4523.T-JP, ESALY,	2024-02-13 10:40:34 Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies NEGATIVE 4523.T-JP, SAGE, BIIB, ESALY,
2023-04-25 13:56:40 Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says NEUTRAL ESALY, BIIB, 4523.T-JP, LLY,	2023-03-13 18:40:54 Veterans Health Administration will cover Alzheimer's treatment Leqembi, Eisai says NEUTRAL ESALY, 4523.T-JP, BIIB,	2023-02-23 12:33:51 Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi NEGATIVE 4523.T-JP, ESALY, BIIB,	2023-02-17 15:25:35 Senators call on Medicare to offer broad coverage of Alzheimer's treatments as public pressure grows POSITIVE BIIB, 4523.T-JP, ESALY,
2023-02-17 10:29:11 Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage POSITIVE BIIB, 4523.T-JP, ESALY,

Found 9 articles